文献速递心律失常血脂与心血管预防

房颤合并终末期肾病患者的抗凝治疗与心血管结局

Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本研究基于2007至2013年Medicare按服务收费5%理赔数据,分析房颤合并终末期肾病患者口服抗凝药的使用模式及其与心血管结局的关联。倾向评分匹配后,口服抗凝药与卒中住院或死亡风险无显著关联,但与出血住院和颅内出血风险增加相关。

要点

  • 房颤合并终末期肾病患者口服抗凝药使用率低(36.2%)。
  • 口服抗凝药未降低卒中住院或死亡风险。
  • 口服抗凝药与出血住院及颅内出血风险增加相关。

核心结论

  • 房颤合并终末期肾病患者中口服抗凝药使用与卒中或死亡风险降低无关。
  • 口服抗凝药使用与出血住院和颅内出血风险增加相关。

研究设计与样本

  • 基于2007至2013年Medicare按服务收费5%理赔数据的回顾性队列研究。
  • 纳入8410例房颤合并终末期肾病患者,其中3043例(36.2%)在研究期间曾接受口服抗凝药治疗。
  • 采用倾向评分匹配1519例口服抗凝药患者与3018例未口服抗凝药患者,使用Cox比例风险模型比较结局。

主要发现

  • 口服抗凝药与卒中住院风险无关(HR 1.00;95%CI 0.23-1.35;p=0.97)。
  • 口服抗凝药与死亡风险无关(HR 1.02;95%CI 0.94-1.10;p=0.62)。
  • 口服抗凝药与出血住院风险增加相关(HR 1.26;95%CI 1.09-1.46;p=0.0017)。
  • 口服抗凝药与颅内出血风险增加相关(HR 1.30;95%CI 1.07-1.59;p=0.0094)。

临床怎么用

  • 房颤合并终末期肾病患者使用口服抗凝药需权衡出血风险,不应默认其带来卒中或死亡获益。
  • 需探索终末期肾病合并房颤患者的替代卒中预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) is common in patients with end-stage renal disease (ESRD). The impact of oral anticoagulation (OAC) in ESRD patients is uncertain. OBJECTIVES: The purpose of this study was to describe patterns of OAC use in ESRD patients with AF and their associations with cardiovascular outcomes. METHODS: Using Medicare fee-for-service 5% claims data from 2007 to 2013, we analyzed treatment and outcomes in a cohort of patients with ESRD and AF. Prescription drug benefit information was used to determine the timing of OAC therapy. Cox proportional hazards modeling was used to compare outcomes including death, all-cause stroke, ischemic stroke, hemorrhagic stroke, and bleeding hospitalizations in ESRD patients treated with or without OAC. RESULTS: The cohort included 8,410 patients with AF and ESRD. A total of 3,043 (36.2%) patients were treated with OAC at some time during the study period. Propensity scores used to match 1,519 patients with AF and ESRD on OAC with 3,018 ESRD patients without OAC. Treatment with OAC was not associated with hospitalization for stroke (hazard ratio [HR]: 1.00; 95% confidence interval [CI]: 0.23 to 1.35; p = 0.97) or death (HR: 1.02; 95% CI: 0.94 to 1.10; p = 0.62). OAC was associated with an increased risk of hospitalization for bleeding (HR: 1.26; 95% CI: 1.09 to 1.46; p = 0.0017) and intracranial hemorrhage (HR: 1.30; 95% CI: 1.07 to 1.59; p = 0.0094). CONCLUSIONS: OAC utilization was low in patients with AF and ESRD. We found no association between OAC use and reduced risk of stroke or death. OAC use was associated with increased risks of hospitalization for bleeding or intracranial hemorrhage. Alternative stroke prevention strategies are needed in patients with ESRD and AF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Pokorney SD, Black-Maier E, Hellkamp AS, et al. Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. J Am Coll Cardiol. 2020. PMID: 32192656. doi:10.1016/j.jacc.2020.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。